Cascadian Therapeutics, Inc. (CASC) Issues Quarterly Earnings Results
Cascadian Therapeutics, Inc. (NASDAQ:CASC) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.06, Briefing.com reports. During the same period last year, the business earned ($1.57) earnings per share.
Shares of Cascadian Therapeutics (CASC) traded down 4.026% on Thursday, reaching $3.695. The company had a trading volume of 183,935 shares. The firm’s market cap is $181.96 million. Cascadian Therapeutics has a one year low of $0.84 and a one year high of $6.72. The company has a 50-day moving average price of $3.93 and a 200-day moving average price of $4.02.
Several equities research analysts have weighed in on CASC shares. ValuEngine lowered Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research raised Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Monday, July 17th. Cantor Fitzgerald reissued a “hold” rating and set a $4.00 price target on shares of Cascadian Therapeutics in a report on Wednesday, May 10th. Cowen and Company reissued a “buy” rating on shares of Cascadian Therapeutics in a report on Tuesday, May 9th. Finally, BTIG Research assumed coverage on Cascadian Therapeutics in a report on Friday, April 21st. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $6.17.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.